Literature DB >> 27091576

Postnatal knockdown of dok-7 gene expression in mice causes structural defects in neuromuscular synapses and myasthenic pathology.

Takahiro Eguchi1, Tohru Tezuka1, Sadanori Miyoshi1, Yuji Yamanashi1.   

Abstract

The neuromuscular junction (NMJ) is a synapse between a motor neuron and skeletal muscle and is required for muscle contraction. The formation and maintenance of NMJs are governed by the muscle-specific receptor tyrosine kinase MuSK. We previously showed that the muscle cytoplasmic protein Dok-7 is an essential activator of MuSK. Indeed, mice lacking either Dok-7 or MuSK form no NMJs, and defects in the human DOK7 gene underlie a congenital myasthenic syndrome (an NMJ disorder). However, it remains unproven whether Dok-7 is required for the postnatal maintenance of NMJs. In this study, we generated recombinant adeno-associated virus (AAV) vectors encoding short hairpin RNAs targeting the mouse dok-7 gene (AAV-shD7). Systemic administration of AAV-shD7 into 2-week-old mice down-regulated dok-7 expression in muscle and induced myasthenic symptoms including reduction in body weight and motor function. Moreover, AAV-shD7 treatment suppressed MuSK-dependent gene expression of NMJ components and reduced the size of NMJs. These results demonstrate that correct, physiological levels of dok-7 expression are required for the postnatal maintenance of NMJs.
© 2016 Molecular Biology Society of Japan and John Wiley & Sons Australia, Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27091576     DOI: 10.1111/gtc.12370

Source DB:  PubMed          Journal:  Genes Cells        ISSN: 1356-9597            Impact factor:   1.891


  7 in total

1.  Control of CRK-RAC1 activity by the miR-1/206/133 miRNA family is essential for neuromuscular junction function.

Authors:  Ina Klockner; Christian Schutt; Theresa Gerhardt; Thomas Boettger; Thomas Braun
Journal:  Nat Commun       Date:  2022-06-08       Impact factor: 17.694

2.  DOK7 gene therapy enhances motor activity and life span in ALS model mice.

Authors:  Sadanori Miyoshi; Tohru Tezuka; Sumimasa Arimura; Taro Tomono; Takashi Okada; Yuji Yamanashi
Journal:  EMBO Mol Med       Date:  2017-07       Impact factor: 12.137

3.  The beta-adrenergic agonist salbutamol modulates neuromuscular junction formation in zebrafish models of human myasthenic syndromes.

Authors:  Grace McMacken; Dan Cox; Andreas Roos; Juliane Müller; Roger Whittaker; Hanns Lochmüller
Journal:  Hum Mol Genet       Date:  2018-05-01       Impact factor: 6.150

Review 4.  Signal Exchange through Extracellular Vesicles in Neuromuscular Junction Establishment and Maintenance: From Physiology to Pathology.

Authors:  Serena Maggio; Paola Ceccaroli; Emanuela Polidori; Andrea Cioccoloni; Vilberto Stocchi; Michele Guescini
Journal:  Int J Mol Sci       Date:  2019-06-08       Impact factor: 5.923

Review 5.  The Neuromuscular Junction in Health and Disease: Molecular Mechanisms Governing Synaptic Formation and Homeostasis.

Authors:  Pedro M Rodríguez Cruz; Judith Cossins; David Beeson; Angela Vincent
Journal:  Front Mol Neurosci       Date:  2020-12-03       Impact factor: 5.639

6.  Motor function recovery: deciphering a regenerative niche at the neuromuscular synapse.

Authors:  Diego Zelada; Francisca Bermedo-García; Nicolás Collao; Juan P Henríquez
Journal:  Biol Rev Camb Philos Soc       Date:  2020-12-17

7.  Neuromuscular junction-specific genes screening by deep RNA-seq analysis.

Authors:  Tiankun Hui; Hongyang Jing; Xinsheng Lai
Journal:  Cell Biosci       Date:  2021-05-01       Impact factor: 9.584

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.